Ipsen News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

21.05.25	Ipsen S.A. - Annual General Meeting held on 21 May 2025 (GlobeNewswire)
11.06.24	FDA Fast-Tracks Ipsen And Genfit's New Liver Disease Treatment, Iqirvo (Benzinga)
27.01.23	Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U. (Businesswire)
20.01.23	Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde® Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GI (Businesswire)
09.01.23	Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases (Businesswire)
23.12.22	Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva (Businesswire)
09.11.22	Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (Businesswire)
27.10.22	Ipsen Delivers Strong Sales Growth in the First Nine Months of 2022 and Confirms Its Full-year Guidance (Businesswire)
25.10.22	Ipsen Statement on Updated Timeline for Palovarotene FDA Advisory Committee Meeting (Businesswire)
12.08.22	Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology (Businesswire)
05.08.22	Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022 (Businesswire)
03.08.22	Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer (Businesswire)
01.08.22	Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-Oncology Candidates From Marengo’s STAR Platform Into the Clinic (Businesswire)
29.06.22	Ipsen Announces U.S. FDA Priority Review for palovarotene New Drug Application in Patients With Fibrodysplasia Ossificans Progressiva Following Resubmission (Businesswire)
27.06.22	Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology (Businesswire)
09.06.22	Ipsen Receives Positive Opinion in Europe for Dysport® in the Management of Urinary Incontinence in Adults With Neurogenic Detrusor Overactivity Due to Multiple Sclerosis or Spinal Cord Injury (Businesswire)
01.06.22	Ipsen Initiates a Share Buy-Back Program to Cover Its Employee Free Share-Allocation Plan (Businesswire)
25.02.19	Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 billion (Reuters)
14.04.17	Ipsen Appoints Dr. Alexandre Lebeaut as Executive Vice-President, R&D, and Chief Scientific Officer (Businesswire)
11.07.14	Nestlé-Tochter Galderma baut Kooperation mit Ipsen bei Neurotoxinen aus (AWP)
11.07.14	SMI schliesst tiefer -- Dax beendet Woche fast auf Nullpunkt -- US-Aktienmarkt schliesst versöhnlich -- Ölpreise erneut unter Druck (finanzen.ch)
24.01.12	Santhera erhält Fipamezole-Rechte von Ipsen zurück; Fokus bleibt auf Catena (AF) (AWP)
28.08.09	CORRECTING AND REPLACING: Ipsen’s Half Year 2009 Results (Businesswire)
28.08.09	Ipsen’s Half Year 2009 Results (Businesswire)
26.06.09	Ipsen: AZZALURE(R) Approved in Germany for Aesthetic Use in the Treatment of Glabellar Lines (Businesswire)
30.04.09	Ipsen and Medicis: FDA Approves DysportTM for Therapeutic and Aesthetic Uses (Businesswire)
12.03.09	Ipsen: AZZALURE® Approved in the UK for Aesthetic Use in the Treatment of Glabellar Lines (Businesswire)
02.03.09	Ipsen’s Full Year 2008 Results (Businesswire)
19.01.09	Ipsen: "Creating the Future: New Challenges in Biology and Medicine” (Businesswire)
08.01.09	Ipsen Provides Update on R&D Pipeline and Business Opportunities at Its Investor Day (Businesswire)
29.12.08	FDA Issues Complete Response Letter to Ipsen for Dysport® Biologics License Application (Businesswire)
12.12.08	Ipsen: AFEP / MEDEF Recommendations on Compensation of Executive Directors (Businesswire)
30.09.08	Ipsen: FDA's First-Cycle Review of Dysport(R) to Be Completed by Year-End (Businesswire)
29.08.08	Ipsen's Half Year 2008 Results and Update on Standalone Financial Objectives for the Full Year 2008 (Businesswire)
31.07.08	Ipsen's First Half 2008 Sales, Outlook for the Full Year 2008 and R&D Pipeline Update (Businesswire)
19.05.08	Ipsen and Medicis Announce Acceptance of Reloxin(R) BLA in Aesthetics by FDA (Businesswire)
12.05.08	Tercica Reports First Quarter 2008 Financial Results (Businesswire)
01.05.08	Tercica to Hold 2008 First Quarter Financial Results Conference Call May 12 (Businesswire)
18.03.08	Ipsen: Appointment of Frederic Babin as Executive Vice President, Human Resources (Businesswire)
29.02.08	Tercica Announces Changes to Its Board of Directors and Management Team (Businesswire)
27.02.08	Tercica Reports Fourth Quarter and Year-End 2007 Financial Results (Businesswire)
27.02.08	Ipsen's Full Year 2007 Results and Financial Objectives for the Full Year 2008 (Businesswire)
21.02.08	EMEA Recommends Marketing Authorisation of Ipsen's Adenuric(R) (Febuxostat) for the Treatment of Chronic Hyperuricaemia in Gout (Businesswire)
22.01.08	Tercica Initiates Phase II Clinical Trial with Next-Generation Growth Hormone Product for the Treatment of Short Stature (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Roche Hldg G	265.50	2.04 %	K V
Lonza Grp	569.20	1.43 %	K V
Novartis	94.03	1.40 %	K V
Geberit	613.00	0.79 %	K V
Part Grp Hldg	1’102.00	0.78 %	K V
CieFinRichemont	154.85	-0.67 %	K V
Kuehne+Nagel Int	185.05	-0.80 %	K V
ABB	46.54	-1.61 %	K V
Logitech Intl	68.44	-2.34 %	K V
Holcim	91.02	-2.57 %	K V

Ipsen Aktie VALOR 2348805 / ISIN FR0010259150

Nachrichten zu Ipsen

Aktien Top/Flop

Meistgelesene Nachrichten